» Articles » PMID: 16877359

Alzheimer's Disease-like Tau Neuropathology Leads to Memory Deficits and Loss of Functional Synapses in a Novel Mutated Tau Transgenic Mouse Without Any Motor Deficits

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 2006 Aug 1
PMID 16877359
Citations 169
Authors
Affiliations
Soon will be listed here.
Abstract

Tau transgenic mice are valuable models to investigate the role of tau protein in Alzheimer's disease and other tauopathies. However, motor dysfunction and dystonic posture interfering with behavioral testing are the most common undesirable effects of tau transgenic mice. Therefore, we have generated a novel mouse model (THY-Tau22) that expresses human 4-repeat tau mutated at sites G272V and P301S under a Thy1.2-promotor, displaying tau pathology in the absence of any motor dysfunction. THY-Tau22 shows hyperphosphorylation of tau on several Alzheimer's disease-relevant tau epitopes (AT8, AT100, AT180, AT270, 12E8, tau-pSer396, and AP422), neurofibrillary tangle-like inclusions (Gallyas and MC1-positive) with rare ghost tangles and PHF-like filaments, as well as mild astrogliosis. These mice also display deficits in hippocampal synaptic transmission and impaired behavior characterized by increased anxiety, delayed learning from 3 months, and reduced spatial memory at 10 months. There are no signs of motor deficits or changes in motor activity at any age investigated. This mouse model therefore displays the main features of tau pathology and several of the pathophysiological disturbances observed during neurofibrillary degeneration. This model will serve as an experimental tool in future studies to investigate mechanisms underlying cognitive deficits during pathogenic tau aggregation.

Citing Articles

Limitations and Applications of Rodent Models in Tauopathy and Synucleinopathy Research.

Szegvari E, Holec S, Woerman A J Neurochem. 2025; 169(3):e70021.

PMID: 40026260 PMC: 11874209. DOI: 10.1111/jnc.70021.


Deletion of Murine APP Aggravates Tau and Amyloid Pathologies in the 5xFADXTg30 Alzheimer's Disease Model.

Ando K, Kosa A, Mehadji Y, Lasri H, Lopez-Gutierrez L, Quintanilla-Sanchez C Biomolecules. 2025; 15(2).

PMID: 40001463 PMC: 11853399. DOI: 10.3390/biom15020159.


Allosteric Modulation of Pathological Ataxin-3 Aggregation: A Path to Spinocerebellar Ataxia Type-3 Therapies.

Silva A, Duarte-Silva S, Martins P, Rodrigues B, Serrenho D, Vilasboas-Campos D bioRxiv. 2025; .

PMID: 39896516 PMC: 11785186. DOI: 10.1101/2025.01.22.633970.


Microglial Responses to Alzheimer's Disease Pathology: Insights From "Omics" Studies.

Reid A, Jayadev S, Prater K Glia. 2025; 73(3):519-538.

PMID: 39760224 PMC: 11801359. DOI: 10.1002/glia.24666.


The neural basis of neuropsychiatric symptoms in Alzheimer's disease.

Zhang N, Zhang S, Zhang L, Tao H, Zhang G Front Aging Neurosci. 2024; 16:1487875.

PMID: 39703925 PMC: 11655510. DOI: 10.3389/fnagi.2024.1487875.


References
1.
Hirrlinger P, Scheller A, Braun C, Quintela-Schneider M, Fuss B, Hirrlinger J . Expression of reef coral fluorescent proteins in the central nervous system of transgenic mice. Mol Cell Neurosci. 2005; 30(3):291-303. DOI: 10.1016/j.mcn.2005.08.011. View

2.
Casseron W, Azulay J, Guedj E, Gastaut J, Pouget J . Familial autosomal dominant cortico-basal degeneration with the P301S mutation in the tau gene: an example of phenotype variability. J Neurol. 2005; 252(12):1546-8. DOI: 10.1007/s00415-005-0880-2. View

3.
Bronner I, Ter Meulen B, Azmani A, Severijnen L, Willemsen R, Kamphorst W . Hereditary Pick's disease with the G272V tau mutation shows predominant three-repeat tau pathology. Brain. 2005; 128(Pt 11):2645-53. DOI: 10.1093/brain/awh591. View

4.
Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K . Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci. 2005; 25(46):10637-47. PMC: 6725849. DOI: 10.1523/JNEUROSCI.3279-05.2005. View

5.
Yasuda M, Nakamura Y, Kawamata T, Kaneyuki H, Maeda K, Komure O . Phenotypic heterogeneity within a new family with the MAPT p301s mutation. Ann Neurol. 2005; 58(6):920-8. DOI: 10.1002/ana.20668. View